Trial Profile

Phase 1 and Dose Expansion Study of APR-246 in Combination With Acalabrutinib or Venetoclax-based Therapy in Subjects With R/R NHL Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 17 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Eprenetapopt (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
Focus Adverse reactions
Sponsors Aprea Therapeutics

04 Aug 2023 Status changed from suspended to discontinued.
01 Jun 2022 Status changed from active, no longer recruiting to suspended.
09 Dec 2021 According to an Aprea Therapeutics media release, the company have addressed the FDA concerns and receive clearance to proceed with future clinical study of eprenetapopt in non-Hodgkins lymphomas

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com